Loading clinical trials...
Loading clinical trials...
A Multicenter, 2-Part, 6-Week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of AEVI-001 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder and With or Without Copy Number Variants in Specific Genes Implicated in Glutamatergic Signaling and Neuronal Connectivity
Conditions
Interventions
AEVI-001
Placebo
Locations
1
United States
Aevi Genomic Medicine
Wayne, Pennsylvania, United States
Start Date
August 28, 2017
Primary Completion Date
September 24, 2018
Completion Date
October 1, 2018
Last Updated
July 7, 2021
NCT07189442
NCT06123741
NCT06847165
NCT04175041
NCT07459699
NCT07439276
Lead Sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions